Napabucasin targets stemness markers, effectively killing stemness-high cancer cells from various tumors, except in prostate cancer (PCa). It inhibits PCa cell proliferation, motility, survival, and colony formation, while increasing apoptosis and sensitivity to docetaxel. Napabucasin also blocks sphere formation and kills prostate cancer stem cells (PrCSCs) and suppresses stemness gene expression. In PC-3 and 22RV1 cells, it reduces proliferation significantly from day 2 to 5 compared to controls (P<0.05) [1].
体内研究
Napabucasin (40 mg/kg) or Docetaxel significantly reduces tumor growth and volume in xenograft models, with Napabucasin showing even lower tumor volumes than Docetaxel in 22RV1 models (P<0.05). Both treatments also significantly reduce tumor weight compared to PBS (P<0.05) [1].
体外研究
Napabucasin targets stemness markers, effectively killing stemness-high cancer cells from various tumors, except in prostate cancer (PCa). It inhibits PCa cell proliferation, motility, survival, and colony formation, while increasing apoptosis and sensitivity to docetaxel. Napabucasin also blocks sphere formation and kills prostate cancer stem cells (PrCSCs) and suppresses stemness gene expression. In PC-3 and 22RV1 cells, it reduces proliferation significantly from day 2 to 5 compared to controls (P<0.05) [1].
Napabucasin 细胞研究
细胞系
浓度
检测类型
检测时间
活动说明
数据源
human DU145 cells
Function assay
72 h
Anticancer activity against human DU145 cells after 72 hrs by XTT assay, IC50=0.02304 μM
18829316
human HaCaT cells
Function assay
48 h
Antihyperproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopy, IC50=0.5 μM
22845014
human HaCaT cells
Proliferation assay
Antiproliferative activity against human HaCaT cells, IC50=0.5 μM
10479319
KB cells
Cytotoxic assay
Effective cytotoxic dose against KB cells was evaluated, ED50=4.2 μM
搜索
